Whereas single transgenic mice carrying a melanocyte-specific activating NRAS mutation alone produced few tumors over a long period of time, the overwhelming majority of double transgenic mice (activated β-catenin with activated NRAS) developed melanomas over a shorter span, and many of them developed multiple primary tumors. Here, NRAS is linked to melanoma.